Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant...
Eligibility criteria include untreated advanced clear cell RCC, ECOG PS 0 or 1, measurable disease by RECIST 1.1 and adequate organ function and excludes patients who have previously received immunotherapy. The